Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.47 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.47 |
| ▸ | MDK | P21741 | 2/20 | 0.42 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CD69 | Q07108 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22317580 | 1.00 | MAPK1 (0.55) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL21257124 | 1.00 | MAPK1 (0.55) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL18736059 | 1.00 | MAPK1 (0.55) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL22021752 | 0.98 | MAPK1 (0.53) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL20904109 | 0.97 | MAPK1 (0.54) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL24420970 | 0.96 | MAPK1 (0.51) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL24052100 | 0.96 | MAPK1 (0.51) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL23240693 | 0.96 | MAPK1 (0.51) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL18736063 | 0.96 | MAPK1 (0.51) | MAPK1LGALS3LGALS8LGALS4MDK | |
| SCHEMBL27059366 | 0.96 | MAPK1 (0.51) | MAPK1LGALS3LGALS8LGALS4MDK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840691-B2 | Compound and application thereof | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11840691-B2 | Compound and application thereof | GALNT6, GALNT3, GALNT14 | MAPK1 2679/4885LGALS3 70/4885LGALS8 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.